This educational program consists of three presentations on residual CVD risk with a focus on triglycerides and triglyceride-rich lipoproteins.
Prof. Libby gives an introduction to the symposium about the evolving role of triglycerides in residual CV risk, that was held during the virtual ESC 2020 congress.
Prof. Bhatt gives a recap of the findings of the main REDUCE-IT trial with icosapent ethyl and of subsequent analyses.
In patients with dyslipidemia, levels of apoB-containing lipoproteins are elevated, containing both triglycerides and cholesterol. What are the treatment targets of these non-LDL-c parameters and how can these be achieved?
What is the role of triglyceride-rich lipoproteins in residual risk in patients with ASCVD?
Expert discussion on novel opportunities tackling residual cardiovascular risk: The evolving role of triglycerides.